Vericel (VCEL) Other Non-Current Liabilities (2010 - 2026)
Vericel (VCEL) reported Other Non-Current Liabilities of $1.9 million for Q1 2026, up 1.68% on a YoY basis from $1.8 million in Q1 2025, and down 0.9% sequentially from $1.9 million in Q4 2025.
Vericel (VCEL) Other Non-Current Liabilities (2010 - 2026) Analysis & Trends
Vericel (VCEL) has 17 years of Other Non-Current Liabilities data on file, last reported at $1.9 million in Q1 2026.
- For the quarter ending Q1 2026, Other Non-Current Liabilities rose 1.68% year-over-year to $1.9 million; the trailing twelve-month figure through Mar 2026 stood at $1.9 million (up 1.68% YoY), and the FY2025 full-year result was $1.9 million, up 116.44% from the prior year.
- Other Non-Current Liabilities fell to $1.9 million in Q1 2026, from $1.9 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $1.9 million in Q4 2025 to a low of $19000.0 in Q1 2022.
- A 5-year average of $761142.9 and a median of $220500.0 in 2024 frame the typical range for Other Non-Current Liabilities.
- Across the five-year window, Other Non-Current Liabilities tumbled 66.67% in 2022 and soared 1100.0% in 2025, its largest moves.
- Tracing VCEL's Other Non-Current Liabilities over 5 years: stood at $21000.0 in 2022, then soared by 376.19% to $100000.0 in 2023, then surged by 776.0% to $876000.0 in 2024, then surged by 116.44% to $1.9 million in 2025, then retreated by 0.9% to $1.9 million in 2026.
- Business Quant data shows VCEL's Other Non-Current Liabilities at $1.9 million in Q1 2026, $1.9 million in Q4 2025, and $1.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Vericel | 2.30 Bn | 2.15 Bn | 49.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.88 Mn |
| Dec 31, 2025 | 1.90 Mn |
| Sep 30, 2025 | 1.67 Mn |
| Jun 30, 2025 | 1.66 Mn |
| Mar 31, 2025 | 1.85 Mn |
| Dec 31, 2024 | 876,000.00 |
| Sep 30, 2024 | 243,000.00 |
| Jun 30, 2024 | 198,000.00 |
| Mar 31, 2024 | 154,000.00 |
| Dec 31, 2023 | 100,000.00 |
| Sep 30, 2023 | 65,000.00 |
| Jun 30, 2023 | 28,000.00 |
| Jun 30, 2022 | 21,000.00 |
| Mar 31, 2022 | 19,000.00 |
| Dec 31, 2021 | 44,000.00 |
| Sep 30, 2021 | 42,000.00 |
| Jun 30, 2021 | 62,000.00 |
| Mar 31, 2021 | 57,000.00 |
| Dec 31, 2020 | 76,000.00 |
| Sep 30, 2020 | 74,000.00 |